This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01695239?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
